Treatment with dasatinib or nilotinib in chronic myeloid leukemia patients who failed to respond to two previously administered tyrosine kinase inhibitors – a single center experience

Overview of attention for article published in Clinics, August 2015

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (55th percentile)
Above-average Attention Score compared to outputs of the same age and source (58th percentile)

Mentioned by

policy: 1 policy source

Citations

dimensions_citation: 21 Dimensions

Readers on

mendeley: 45 Mendeley

Summary Policy documents Dimensions citations

So far, Altmetric has seen 1 policy document that references this research output.

Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia: Committee papers

Cited by National Institute for Health and Care Excellence on 06 Feb 2017

The National Institute for Health and Care Excellence (NICE) in the UK provides national guidance and advice to improve health and social care.

This page shows the most recent policy documents that mention this research output.

Click here to find out how to access more activity.